# CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma

> **NCT03150316** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 18 (estimated)

## Conditions studied

- Myeloma, Multiple

## Interventions

- **DRUG:** Treat Regimen

## Key facts

- **NCT ID:** NCT03150316
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-10
- **Primary completion:** 2020-06-30
- **Final completion:** 2021-09-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150316, "CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03150316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*